FORT LAUDERDALE, FL — (Marketwired) — 01/16/15 — OmniComm Systems, Inc., (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, announces record growth in total contract value for 2014. Total contract value grew over 141% from 2013. A significant portion, 33%, of total contract value, came from companies that are within the 10 largest global contract research organizations (CRO) and pharmaceutical companies. The company experienced healthy year-over-year contract value growth from new and existing clients, 388% and 51% respectively.
TrialMaster® electronic data capture (EDC) suite accounted for 64% of total contract value for 2014. Innovation is the cornerstone of TrialMaster–s continued market adoption. Managing the clinical data lifecycle from study setup to submission, TrialMaster–s intuitive, integrated and interoperable technology, combined with OmniComm–s unsurpassed industry expertise, provides comprehensive solutions that enable a best-in-class e-Clinical enterprise.
“The tremendous increase in new client adoption confirms our market position as the –EDC specialist–,” said Dr. Kuno van der Post, senior vice president of business development. “OmniComm is the only company that can offer our diverse clients the right EDC tools that fit their unique clinical research needs, from Phase I through Phase IV. Moreover, today–s decisions are no longer about finding a replacement for paper; it–s about replacing aging and unsuitable EDC technology. Our open and interoperable technology, combined with expertise from our Transformation Services organization, have made extracting and replacing yesterday–s EDC technology with OmniComm–s specialized EDC platforms, a much easier process for our clients. The significant increase of repeat business from our existing clients is proof that OmniComm continues to transact at the highest level of innovation, service and support.”
TrialOne®, the market leading technology for early phase site automation, saw significant market adoption in 2014, accounting for 29% of 2014 total contract value. Phase I clinics are adopting TrialOne as the best-in-class technology that provides increased performance, functionality and better business decision making tools. TrialOne was selected by early phase clinics around the globe to provide a competitive advantage in the marketplace, as well as make day-to-day operations more efficient, leading to higher quality trials, easier access to data, and enhanced control of patient safety.
For 2014 OmniComm was included in Software 500 ranking of the world–s largest software and service providers. The Software 500 is a revenue-based ranking of the world–s largest software and services suppliers, targeting medium to large enterprises and is based on total software and services revenue for 2014. This includes revenues from software licenses, maintenance and support, training and software-related services and consulting. And for a third year in a row OmniComm was ranked in top 150 publicly traded companies in Florida.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world–s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit .
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
You must be logged in to post a comment Login